St Vincents Hospital

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Prostate cancer2 trials
• Childhood cancers1 trial
• Chronic lymphocytic leukaemia1 trial
• Head and neck cancer1 trial
• Heart failure1 trial
• HIV1 trial

Phase

• Phase 33 trials
• Phase 22 trials

Status

• Active, not recruiting4 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Australian and New Zealand Urogenital and Prostate Cancer Trials Group2 trials
• Corvia Medical1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• Janssen Research & Development, LLC1 trial
• Monash University1 trial

Running trials

• Recruiting

  Working Out M0 Bipolar Androgen Therapy

  NCT06594926· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source

  Contact: Angelina Lay

• Active, not recruiting

  A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  NCT06208150· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

  NCT05556720· Phase 3· Monash University· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Corvia Medical· Source

• Active, not recruiting

  Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

  NCT04419402· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer1 recruiting

Closed trials

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source